Royalty Pharma RPRX
Royalty Pharma is the largest buyer of biopharmaceutical royalties: it acquires rights to future revenues from third-party drugs in exchange for upfront payments, generating recurring income without bearing development costs. Royalty Pharma shows strong momentum (9.34) and 16.5% revenue growth, but its financial health is weighed down by net debt of 5.22x EBITDA and negative cash conversion. The Phase 3 failure of Pelacarsen is a material risk to future royalties, although its diversified portfolio and a forward P/E of 10.15 offer some appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Royalty Pharma is the largest buyer of biopharmaceutical royalties: it acquires rights to future revenues from third-party drugs in exchange for upfront payments, generating recurring income without bearing development costs. Royalty Pharma shows strong momentum (9.34) and 16.5% revenue growth, but its financial health is weighed down by net debt of 5.22x EBITDA and negative cash conversion. The Phase 3 failure of Pelacarsen is a material risk to future royalties, although its diversified portfolio and a forward P/E of 10.15 offer some appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.0 |
| Quality / Moat | 4.1 |
| Valuation | 4.0 |
| Growth | 3.7 |
| Dividend | 6.4 |
| Momentum | 9.3 |
| Risk & Context | 8.1 |
OVERALL SCORE: 5.3/10
Context and risks
Royalty Pharma's business model depends on future drug revenues, which are subject to regulatory approval and US drug pricing policy. The Phase 3 failure of Pelacarsen underscores this risk, which is not reflected in current financial metrics.
News considered in the analysis
- Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts — La búsqueda de nuevas fuentes de crecimiento (IA, China) es positiva pero especulativa y aún no se refleja en los números.
- Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? — Artículo de opinión que compara dos inversiones, sin información nueva sobre Royalty Pharma.
- Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run — La valoración tras la fuerte subida es una preocupación, pero el PER forward de 10.15 sugiere que el mercado ya descuenta un crecimiento futuro.
- Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns — Un análisis de valoración sugiere que la acción está infravalorada, lo que podría atraer interés de compra.
- Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? — El fracaso de Pelacarsen en Fase 3 es un evento material que afecta a una de sus regalías clave, aunque la cartera diversificada mitiga el impacto.
Verdict: Hold, with caution. The strong rally and the Pelacarsen failure justify waiting for a better entry point or more clarity on the impact on royalties.
Main risk: The failure of a key drug in Phase 3 (Pelacarsen) and dependence on regulatory approvals and US drug pricing policy are the biggest risks to Royalty Pharma's royalty model.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →